API market to touch US$185.9 billion by 2020
Global API market driven by the rising abbreviated new drug applications and the growth in filing drug master files from several Indian firms, says Transparency Market Research.
A new Transparency Market Research report states that the global active pharmaceuticals ingredients (APIs) market stood at US$119.7 billion in 2014 and is predicted to reach US$185.9 billion by 2020. It is expected to expand at a CAGR of 6.50% from 2014 to 2020. The title of the report is "Active Pharmaceutical Ingredients (API) Market: (Branded/Generic/Over-the-counter, Chemical/Biological, Captive/Contract Manufactured, by Geography, and by Therapeutic Area) — Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014–2020".
The global pharmaceutical industry has suffered enormously due to patent expiry of blockbuster drugs in the past few years. However, this has facilitated a surge in the demand for low-cost substitutes across the globe resulting in a boost to active pharmaceutical ingredient (API) manufacturing. The approvals of biosimilars in Europe has added to the total API market revenue, and the recent approval of Novartis' filgrastim biosimilar in the US is expected to continue the upward trend in this market. The overall global APIs market was valued at USD 119.7 billion in 2013 and is anticipated to reach USD 185.9 billion by 2020, expanding at a CAGR of 6.5% during the forecast period from 2014 to 2020.
The global APIs market is driven by the rising abbreviated new drug applications (ANDA). In the past few years, the growth in ANDAs has in turn fuelled the demand for APIs. In addition to this, the growth in filing drug master files (DMFs) from several Indian firms has fueled the overall APIs market. On the other hand, the global APIs market will be constrained by the strict European Union (EU) regulatory policies.
As per the report, the APIs market is fuelled by the rising abbreviated new drug applications and the increasing drug master file filing via Indian companies. The prime opportunity seen in the market is the patent expiry of promising biological drugs. On the other hand, factors such as the stringent EU regulatory policies will impede the growth of the APIs market in the coming years.
On the basis of type of manufacturing, the market is segmented into API contract manufacturing and captive or in-house API manufacturing. Amongst these, the segment of captive or in-house API manufacturing is experiencing a rapid decline in the market for APIs owing to its lack of profitability for the manufacturer and rising degree of competition in the market. Pharmaceutical companies are inclined towards API contract manufacturing rather than in-house API manufacturing owing to the increasing costs of research and development, and the pressure to maintain low prices of finished goods. Thus, outsourcing of API production is increasingly being preferred by manufacturers.
On the basis of type of API, the market is segmented into biological APIs and synthetic chemical APIs. Amongst these, the segment of biological APIs is experiencing the most significant growth rate owing to the huge number of pharmaceutical companies involved in this segment.
The chief players dominant in the market are Boehringer Ingelheim Group, Dr Reddy's Laboratories, Cambrex, BASF, Lonza, Hospira, Mylan, Teva Pharmaceutical Industries, Novartis, and Pfizer.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance